FranceTuberculosis profile
Population  2017 65 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.35 (0.33–0.38) 0.55 (0.51–0.58)
Mortality (HIV+TB only) 0.15 (0.081–0.25) 0.24 (0.13–0.39)
Incidence  (includes HIV+TB) 5.9 (5.1–6.6) 9 (7.9–10)
Incidence (HIV+TB only) 0.83 (0.49–1.3) 1.3 (0.76–1.9)
Incidence (MDR/RR-TB)** 0.11 (0.075–0.14) 0.16 (0.12–0.22)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.25 (0.21–0.3) 1.8 (1.5–2.2) 2.1 (1.7–2.5)
Males 0.29 (0.23–0.34) 3.5 (2.8–4.1) 3.8 (3.1–4.4)
Total 0.54 (0.47–0.62) 5.3 (4.6–6) 5.9 (5.1–6.6)
TB case notifications, 2017  
Total cases notified 5 131
Total new and relapse 4 839
          - % tested with rapid diagnostics at time of diagnosis 0%
          - % with known HIV status  
          - % pulmonary 72%
          - % bacteriologically confirmed among pulmonary 71%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 83% (73–94)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.09 (0.07–0.11)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive    
          - on antiretroviral therapy    
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  65
(48–82)
Estimated % of TB cases with MDR/RR-TB 1% (0.65–1.5) 10% (7.1–15)  
% notified tested for rifampicin resistance 74% 98% 4 221
MDR/RR-TB cases tested for resistance to second-line drugs   79
Laboratory-confirmed cases MDR/RR-TB: 79, XDR-TB: 10
Patients started on treatment **** MDR/RR-TB: 79, XDR-TB: 10
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 54% 4 623
Previously treated cases, excluding relapse, registered in 2016 51% 284
HIV-positive TB cases registered in 2016    
MDR/RR-TB cases started on second-line treatment in 2015    
XDR-TB cases started on second-line treatment in 2015    
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2018  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2019-05-22 Data: www.who.int/tb/data